Peptide Recepter Radiotherapy (PRRT) is one of the most effective treatments for patients with Neuroendocrine Cancer.  In particular, therapy with Lu-177 Octreotate is safe, has relatively few toxic side effects and has been shown to prolong survival by 3 - 6 years. PRRT is emerging from trials to become a mainstream treatment option for NET cancer patients, alongside surgery and Octreotide therapy.

In the coming months, PRRT will be introduced at Singapore General Hospital Nuclear Medicine Department.  This event will help you understand how the treatment works, whether it is suitable in your own case, and at what stage it can be most effective.

Event Details

·         Singapore Management University (SMU), School of Economics, 90 Stamford Road, Room 3.7, Singapore, 178903

·         Thursday 24 February 2011, 5.30pm - 7.00pm

·         Free - Attendance is free and open to the public, but online pre-registration is required.  Recommended for NET cancer patients, family caregivers, and interested physicians.

 Programme 

·         "SGH Nuclear Medicine NET Cancer Services" introductory remarks by Anthony Goh, Senior Consultant, Head of Department of Nuclear Medicine, Singapore General Hospital

·         "Update on Targeted Radiation Therapy for NET Cancer" presentation by Prof. Dr. Irene Virgilio, Head of Department of Nuclear Medicine, Medical University of Innsbruck, Austria

·         Coffee, Tea and Light Snacks